knowledge -WSS

knowledge

author：knowledge 2025-09-30 23:07:45 - browse：4

Fran van Delft for Galapagos

Seeking to differentiate itself from other makers of CAR-T cancer therapies, Galapagos NV on Wednesday announced it had struck a deal with Blood Centers of America to open up dozens of manufacturing sites for its cell-based medicines around the U.S.

Galapagos said it will rely on the partnership, the financial terms of which were not disclosed, as it moves its CAR-Ts for different cancers into pivotal studies and could also help launch those medicines should they win approval. The Belgian company framed the collaboration as one that could help overcome the limitations that have held back access to existing CAR-T therapies from other companies.

CAR-Ts have proven to be potent treatments for certain cancers, but they are complicated medicines to make. Immune cells have to be removed from a patient, shipped to specialty sites, where they’re engineered with cancer-killing abilities, and then returned to the hospital for infusion back into patients. The process, which can take weeks if not months, has put a crunch on the number of patients companies and hospitals are able to treat.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

WSS

IVF, abortion rights issues kick off Biden’s State of the Union

Pushing for an NIH office for post

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

RSV shot was 90% effective at preventing hospitalizations in kids

John Green on his newest strategy for fighting tuberculosis

John Green on his newest strategy for fighting tuberculosis

entertainment

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

23andMe had bad news about my health. I wish a person had delivered it

WuXi out of biotech trade group, U.S. and China relations to blame

At least 13 dead in Texas as scorching temps continue

NEJM study link tiny plastics in blood vessels to heart problems

After affirmative action ruling, medical educators look to 'holistic review'

Amid AI frenzy, a top HHS official's quest to create safeguards

Medical records are filled with copy

John Green on his newest strategy for fighting tuberculosis

Bright Health sells Medicare Advantage business to Molina

Medicare coverage of Wegovy, once blocked, now looks possible

explore

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

Precocious puberty in girls comes with mental health risks

Steward Health Care Massachusetts hospitals face fiscal disaster

Precocious puberty in girls comes with mental health risks

First medicine developed to treat MASH expected to be approved soon

With psoriasis trial ahead, Alumis raises $259 million

hotspot

leisure time

hotspot

Wikipedia